Abstracts tagged "Late-Breaking 2018"

Abstract Number: L06 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards
Mark C. Genovese¹, Kenneth C. Kalunian², David Walker³, Jacques-Eric Gottenberg⁴, Kurt de Vlam⁵, Neelufar Mozaffarian⁶, Beatrix Bartok⁶, Franziska Matzkies⁶, Jie Gao⁶, Ying Guo⁶, Chantal Tasset⁷, John S. Sundy⁶ and Tsutomu Takeuchi⁸, ¹Division of Immunology & Rheumatology, Stanford University, Stanford, CA, ²Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ³Northumbria Healthcare, United Kingdom, United Kingdom, ⁴Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁵Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, ⁶Gilead Sciences, Inc., Foster City, CA, ⁷Galapagos NV, Mechelen, Belgium, Mechelen, Belgium, ⁸Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in phase 2 studies of active RA in patients (pts) with insufficient…
Abstract Number: L07 • 2018 ACR/ARHP Annual Meeting
VIB4920, a Novel, Engineered CD40L Antagonist Decreased Disease Activity and Improved Biomarkers of Immune Activation in Patients with Active Rheumatoid Arthritis in a Phase 1b, Multiple-Ascending Dose Proof-of-Concept Study
Marius Albulescu¹, Ulf Müller-Ladner², Rachel Moate³, Kate Middleton³, Liangwei Wang⁴, Jorn Drappa⁴ and Gabor Illei⁵, ¹Clinical Development, MedImmune, Cambridge, UK, Cambridge, United Kingdom, ²Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus-Liebig-University Giessen, Germany, Bad Nauheim, Germany, ³MedImmune, Cambridge, UK, Cambridge, United Kingdom, ⁴Viela Bio, Gaithersburg, USA, Gaithersburg, MD, ⁵Viela Bio, Gaithersburg, USA, Gaithersberg, MD
Background/Purpose: The CD40L/CD40 co-stimulatory pathway is important for T-cell-dependent antibody production and plays a central role in RA and other autoimmune diseases. VIB4920 (formerly MEDI4920)…
Abstract Number: L08 • 2018 ACR/ARHP Annual Meeting
High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response
Anita Boyapati¹, Jérôme Msihid², Sergio Schwartzman³, Ernest Choy⁴, Mark C. Genovese⁵, Gerd R. Burmester⁶, Gordon Lam⁷, Toshio Kimura¹, Jonathan Sadeh⁸ and Neil M.H. Graham¹, ¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ²Sanofi Chilly-Mazarin, Chilly-Mazarin, NJ, France, ³Hospital for Special Surgery, New York, NY, ⁴CREATE Center, Cardiff University School of Medicine, Cardiff, Great Britain, ⁵Division of Immunology & Rheumatology, Stanford University, Stanford, CA, ⁶Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, ⁷Atrium Health, Charlotte, NC, ⁸Sanofi, Bridgewater, NJ
Background/Purpose: Clinical application of biomarkers to predict response to therapy is the next frontier in RA. Despite the key role of IL-6 in RA, the…
Abstract Number: L09 • 2018 ACR/ARHP Annual Meeting
Comparative Risk of Venous Thromboembolism with Tofacitinib Versus Tumor Necrosis Factor Inhibitors: A Cohort Study of Rheumatoid Arthritis Patients
Rishi J. Desai¹, Ajinkya Pawar², Michael E Weinblatt³ and Seoyoung C. Kim⁴, ¹Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: A potentially increased risk of venous thromboembolism (VTE) was noted in pre-marketing trials of baricitinib, which is a Janus kinase inhibitor (JAK-I). This led…
Abstract Number: L10 • 2018 ACR/ARHP Annual Meeting
Clinical Efficacy of Leflunomide/Hydroxychloroquine Combination Therapy in Patients with Primary Sjogren’s Syndrome: Results of a Placebo-Controlled Double-Blind Randomized Clinical Trial
Timothy R.D.J. Radstake¹, Eefje H.M. van der Heijden², Frederique M. Moret³, Maarten R. Hillen⁴, Ana P. Lopes⁵, Toine Rosenberg⁶, Nard Janssen⁶, Aike A. Kruize⁷ and Joel A.G. van Roon³, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology & Clinical Immunology/ Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Department of Oral-Maxillofacial Surgery, University Medical Center Utrecht, Utrecht, Netherlands, ⁷Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Primary Sjogren’s syndrome (pSS) is a systemic, progressive autoimmune disease characterized by secretory gland dysfunction which lacks effective therapy. Clinical trials in patients with…